Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors
NCT03213678 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 28, 2017
- Completion date
- December 31, 2024
- Enrollment
- 18 (actual)
- Sites
- 127
Conditions
As the registry lists them; a condition with its own page is linked.
advanced malignant solid neoplasm, ann arbor stage iii non-hodgkin lymphoma, ann arbor stage iv non-hodgkin lymphoma, malignant glioma, recurrent ependymoma, recurrent ewing sarcoma, recurrent glioma, recurrent hepatoblastoma, recurrent langerhans cell histiocytosis, recurrent malignant germ cell tumor, recurrent malignant solid neoplasm, recurrent medulloblastoma, recurrent neuroblastoma, recurrent non-hodgkin lymphoma, recurrent osteosarcoma, recurrent peripheral primitive neuroectodermal tumor, recurrent primary central nervous system neoplasm, recurrent rhabdomyosarcoma, recurrent soft tissue sarcoma, refractory langerhans cell histiocytosis, refractory malignant germ cell tumor, refractory malignant solid neoplasm, refractory neuroblastoma, refractory non-hodgkin lymphoma, refractory primary central nervous system neoplasm, rhabdoid tumor, stage iii osteosarcoma ajcc v7, stage iii soft tissue sarcoma ajcc v7, stage iv osteosarcoma ajcc v7, stage iv soft tissue sarcoma ajcc v7, stage iva osteosarcoma ajcc v7, stage ivb osteosarcoma ajcc v7, wilms tumor